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Objectives: Early menarche has been linked to higher risk of type 2 diabetes in Western and Asian societies, yet
whether age at menarche is associated with diabetes in Latin America, where puberty and diabetes may have
different life courses, is unknown. We tested the hypothesis that earlier menarche is associated with higher diabetes
risk in Brazilian adults.
Methods: We used data from 8,075 women aged 35-74 years in the Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil) who had complete information on age at menarche, diabetes status, and covariates. Diabetes was
defined based on self-reported physician diagnosis, medication use, and laboratory variables (fasting glucose,
2-hour glucose, and glycated hemoglobin). Poisson regression was used to generate risk ratios (RR) and 95%
confidence intervals (CI).
Results: Menarche onset < 11 years [vs. 13-14 years (referent)] was associated with higher risk of diabetes
(RR = 1.34; 95% CI: 1.14-1.57) after adjusting for sociodemographic factors, maternal education, maternal and
paternal diabetes, and birth weight. This persisted after further control for BMI at age 20 years and relative leg
length. Additionally, among those not taking diabetes medications, earlier menarche [<11 years vs. 13-14 years
(referent)] was associated with higher % glycated hemoglobin (p < 0.001), alanine aminotransferase (p < 0.001),
triglycerides (p < 0.001), C-reactive protein (p = 0.003), waist circumference (p < 0.001), and BMI measured at
baseline exam (p < 0.001).
Conclusion: These findings support the hypothesis that earlier menarche is associated with greater risk for
adult diabetes and cardiometabolic disease in the Brazilian context.
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Type 2 diabetes has emerged over the past two decades as
a major priority in the health agenda of the underdeveloped
world [1,2]. Developing countries, while still suffering nutri-
tional burdens of scarcity and infection, are faced with the
challenge of managing increasing number of persons with
type 2 diabetes and related micro- and macro-vascular
complications [1,3]. In most low- and middle-income coun-
tries type 2 diabetes is now a leading cause of disease bur-
den due to its long duration and devastating consequences
with respect to quality of life and economic burden [4].
In Brazil, routine surveillance and periodic surveys on
chronic diseases and their risk factors collected by the
Ministry of Health indicate a considerable burden of
diabetes [5]. In addition to the aging Brazilian population,
there has been a rapid rate of migration from rural to
urban environments [6]. Social, behavioral, nutritional,
and environmental changes accompanying this transition
are believed to underlie increases in fatness, insulin resist-
ance, and type 2 diabetes [7].
Once diabetes manifests, its remediation through
behavior change poses a formidable challenge [8,9], and,
even if achieved, it may be too late to reduce incidence
of cardiovascular events [10]. This emphasizes the need
for prevention before type 2 diabetes and its risk factors
develop (i.e., primordial prevention). Identifying valid
markers of pubertal timing could pave the lifecourse
avenue to primordial prevention of type 2 diabetes and
its risk factors at the preclinical stage. Pubertal timing is
influenced by genetic and environmental factors, includ-
ing childhood nutrition and obesity [11-16]. In females,
menarche is the most distinguishable pubertal marker.
There is evidence for a trend towards earlier menarche
in Brazil over the last several decades [17] that is not
explained by childhood obesity [18].
Studies from Western countries [19-23] have reported
that earlier age at menarche is associated with higher
risk of type 2 diabetes. Two Asian studies [24,25] have
found a similar association, while one has not [26]. No
studies have examined this association in an economically
and nutritionally transitioning Latin American population
where contextual influences on age at menarche and type
2 diabetes may differ in important ways.
The aim of this manuscript was to examine age at
menarche in relation to type 2 diabetes in Brazilian adults.
Specifically, we will test the hypotheses that earlier age at
menarche is associated with higher risk of diabetes, after
adjustment for potentially confounding antecedents of
pubertal timing and type 2 diabetes.
Methods
Study participants
The Brazilian Longitudinal Study of Adult Health (Estudo
Longitudinal de Saude do Adulto or ELSA-Brasil) is aprospective cohort study designed to identify risk factors
for diabetes and cardiovascular disease. The details of the
study, including design, eligibility criteria, sources and
methods of recruitment, have been described in detail
elsewhere [27]. Briefly, the cohort comprises 8,217 female
civil servants (from the total sample of 15,105 ELSA-
Brasil participants), aged 35 to 74 years at baseline (2008-
2010), who were sampled from 6 universities or research
institutions (and, in a few instances, also of related educa-
tional or health institutions) located in different regions of
Brazil: the University of São Paulo (n = 2,727); the Federal
Universities of Minas Gerais (n = 1,642), Rio Grande do Sul
(n = 1,172), Bahia (n = 1,189), and Espirito Santo (n = 554);
and the Oswaldo Cruz Foundation (n = 933). All data for
the current analyses were collected at baseline during initial
interviews (~1 hour) and the first clinic visit (~5 hours).
The study was approved by the Research and Ethics
Committees of the institutions involved: Hospital de
Clinicas de Porto Alegre, Universidade Federal do Rio
Grande do Sul, Universidade Federal do Espírito Santo,
Universidade Federal de Minas Gerais, Universidade
Federal da Bahia, Universidade de São Paulo, Fundação
Osvaldo Cruz.
For the current analyses, we excluded women with
missing information for: diabetes status (n = 2), race/
color (n = 74), age at menarche (n = 37), height (n = 3),
sitting height (n = 2), or those who reported menarche
onset < 8 (n = 7) or > 18 years (n = 11). To minimize in-
clusion of type 1 diabetes cases in our diabetes definition
we excluded women who were diagnosed ≤ 30 years and
used insulin as their first medication (n = 6). We created
a dummy variable for missing birth weight (~14%) to
compare the results including versus excluding parti-
cipants with missing birth weight. Our final analytic
sample comprised 8,075 women.
Data collection
Exposure assessment
Age at menarche was assessed by the open-ended ques-
tion, “At what age did you have your first menses?” Adult
retrospective reports of menarcheal age have a moderately
high (r = 0.79) correlation with original adolescent reports
[28]. Height and sitting height (vertex of the head to the
seated buttocks) were measured according to standard
equipment and techniques. Leg length was determined by
taking total height minus sitting height. Relative leg length
(i.e., leg length-to-sitting height ratio) was calculated by
taking leg length divided by sitting height.
Outcome assessment
A 12-hour fasting blood sample was drawn by venipunc-
ture soon after the patient arrived at the baseline clinic
visit. A 2-hour 75-g oral glucose tolerance test (OGTT)
was administered only to participants without known
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(ADVIA Chemistry; Siemens, Deerfield, Illinois). Percent
glycated hemoglobin (A1C) was measured using a high-
pressure liquid chromatography (Bio-Rad Laboratories,
Hercules, California), ad insulin with an immunoenzymatic
assay (ELISA) (Siemens).
Diabetes status was classified using blood glucose mea-
surements and self-reported information. A participant
was considered to have previously diagnosed diabetes
when answering, “yes” to either “Have you been previously
told by a physician that you had diabetes (sugar in
the blood)?” or “Have you used medication for diabetes in
the past 2 weeks?” The remaining ones were evalu-
ated for undiagnosed diabetes based on their laboratory
values and then classified as having diabetes if they
reached the threshold for fasting plasma glucose
(≥ 126 mg/dL), 2-hour post load plasma glucose
(≥ 200 mg/dL), or % A1C (≥ 6.5%).
Additional study outcomes included: alanine amino-
transferase (ALT), measured by a modified Interna-
tional Federation for Clinical Chemistry (enzymatic)
assay (ADVIA Chemistry), high-sensitivity C-reactive
protein (CRP), measured by immunochemistry (nephe-
lometry) (Dade Behring; Siemens), high density lipoprotein
cholesterol (HDL-c), measured by enzymatic colorimetric
assay (ADVIA Chemistry), and triglycerides, measured en-
zymatic colorimetric assay (glycerol phosphate peroxidase)
(ADVIA Chemistry).
Covariate assessment
A comprehensive set of questionnaires, tests, and mea-
surements was carried out to control for co-varying pa-
rameters. Age at baseline visit (years), race/skin color,
educational achievement of the participant and their
mother, parental history of diabetes, birth weight, poly-
cystic ovary syndrome (PCOS), menopause, parity, oral
contraceptive use, hormone therapy, smoking status,
alcohol use, physical activity, and diet were ascertained
by questionnaire. Body mass index (BMI) was calculated
as weight (kg) divided by height (m) squared. Self-recalled
weight was used to determine participants’ BMI at 20
years of age.
Statistical analysis
All analyses were performed using SAS 9.2 (SAS
institute, Cary, NC). We summarized the characteristics
of the cohort using unadjusted means and standard
deviations for continuous variables and percentages for
categorical variables according to menarcheal age cat-
egories (<11, 11-12, 13-14, 15-16, and 17-18 years). The
median age at menarche category, 13-14 years of age,
was used as the reference group for regression models.
We used multivariable Poisson regression with robust
variance [29] to address the main hypothesis of ourstudy. This allowed us to estimate risk ratios (RRs) and
95% confidence intervals (CIs) for diabetes according to
categories of menarcheal age. Multivariable models were
contrasted in a series beginning with model 1 adjusted
for study center and age at interview (years). Model 2
included further adjustment for socio-demographic back-
ground variables: race/skin color, and maternal education
(no formal education, less than eighth grade, completed
eighth grade but not high school, completed high school
but no college, any college). We then additionally adjusted
for maternal and paternal diabetes (model 3) and self-
reported birth weight (<2500 g, 2500-4000 g, >4000 g,
missing) (model 4). As we were interested in the age at
menarche-diabetes association independent of early-adult
BMI, in model 5 we further adjusted for BMI (based on
self-reported weight) at age 20 years (the earliest measure
of this variable). Lastly (model 6), we added relative leg
length to determine if age at menarche is independent
of this marker of early-life growth and developmental
adequacy [30].
We evaluated effect measure modification in the
final model by including cross-product terms between
our exposures and age at interview (median split; < 55
vs. ≥ 55 years), race/skin color (black vs. white), maternal
education (< high school vs. ≥ high school), birth weight
(< 2500 vs. ≥ 2500 g), and BMI at 20 years (25 kg/m2
vs. ≥ 25 kg/m2).
In additional analyses, we used multivariable linear
regression to assess age at menarche categories in
relation to continuous outcome measures for % A1C,
glucose, insulin, alanine aminotransferase, triglycerides,
HDL-c, high sensitivity CRP, waist circumference, and
BMI measured at baseline exam. For these analyses we
excluded women taking diabetes medications in the two
weeks prior to baseline exam. All statistical tests were
two-sided and significance was defined at p < 0.05.
Results
The mean (standard deviation) age at menarche for the
8,075 women eligible for this analysis was 12.7 (1.7)
years of age. As seen from the participant characteristics
according to age at menarche categories presented in
Table 1, earlier menarche age was associated with younger
age at enrollment, higher maternal educational attain-
ment, higher prevalence of paternal diabetes, shorter leg
length (but not sitting height), and higher BMI at age 20.
Women from early and late menarcheal age categories
were more likely to self-identify as black (color), be born
prematurely, have mothers with diabetes, or have PCOS.
Approximately 16.5% of the women included in our
analyses were classified as having diabetes. The associ-
ation between age at menarche and diabetes after
multiple levels of covariate adjustment is shown in Table 2.
Age at menarche <11 years [vs. 13-14 years (referent)] was
Table 1 Mean and standard deviation (unless otherwise noted) of baseline characteristics by age at menarche in
women aged 35-74 years from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
Total <11 years 11–12 years 13–14 years 15–16 years 17–18 years
n (range)* 6943-8075 574-657 2737-3124 2720-3181 749-912 166-204
Age at enrollment 52.0 ± 8.8 51.4 ± 8.4 51.2 ± 8.9 52.3 ± 8.9 53.5 ± 8.7 53.9 ± 8.3
Race/skin color (% black) 17.9 19.6 18.2 16.9 18.1 22.1
Maternal education (%≥ high school) 22.7 26.0 24.8 22.1 16.9 12.1
Participant education (%≥ secondary) 54.5 53.9 58.4 54.8 43.8 40.2
Maternal diabetes (%) 19.9 22.2 20.0 19.4 19.2 21.6
Paternal diabetes (%) 13.6 19.6 14.9 12.0 10.9 10.8
Premature birth (%) 5.6 7.6 5.5 5.1 5.9 6.5
Low birth weight (%) 8.7 9.9 8.7 7.5 12.1 10.8
PCOS (%) 11.1 14.9 11.1 10.7 9.3 11.8
Post-menopause (%) 59.2 60.4 56.6 59.6 64.3 64.7
Five or more births (%) 9.8 9.9 9.6 9.4 11.5 11.3
Leg length (cm) 74.2 ± 4.4 73.0 ± 4.7 74.0 ± 4.4 74.5 ± 4.2 74.7 ± 4.3 75.7 ± 4.2
Sitting height (cm) 84.8 ± 3.7 84.7 ± 4.2 84.8 ± 3.9 84.8 ± 3.5 84.6 ± 3.5 84.4 ± 3.4
BMI (kg/m2) at age 20 years 20.9 ± 3.1 21.9 ± 3.7 21.1 ± 3.1 20.6 ± 2.9 20.4 ± 3.2 20.0 ± 3.1
Abbreviations: PCOS polycystic ovary syndrome.
*n varied for each continuous metabolic parameter included in the model, so the range of n is included in parentheses.
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age, socioeconomic background, maternal and paternal
diabetes, and birth weight (model 4, RR = 1.34; 95% CI:
1.14, 1.57). This association was modestly attenuated after
further adjustment for BMI at age 20 years (model 5,
RR = 1.26; 95% CI: 1.07, 1.49), and relative leg length
(model 6, RR = 1.23; 95% CI: 1.04, 1.44). Further inclusion
of participant education level (less than high school, com-
pleted high school but not college, completed college but
not graduate school, graduate school plus), smoking status
(never, former, current), alcohol use (yes/no), leisure
time physical activity (light, moderate, hard), PCOS
(yes/no), postmenopausal status (yes/no), and parityTable 2 Risk ratios (and 95% confidence intervals) for type 2
from ELSA-Brasil
<11 years 11–12 years
Cases/n 144/657 483/3121
Model 1 1.43 (1.22-1.69) 1.02 (0.91-1.14)
Model 2 1.44 (1.22-1.69) 1.03 (0.92-1.15)
Model 3 1.35 (1.15-1.58) 1.01 (0.91-1.13)
Model 4 1.34 (1.14-1.57) 1.01 (0.90-1.13)
Model 5 1.26 (1.07-1.49) 0.99 (0.88-1.10)
Model 6 1.23 (1.04-1.44) 0.98 (0.87-1.09)
Model 1: adjusted for age at enrollment, and study center.
Model 2: adjusted for variables in model 1 and race/color, and maternal education.
Model 3: adjusted for variables in model 2 and maternal diabetes, and paternal dia
Model 4: adjusted for variables in model 3 and birth weight.
Model 5: adjusted for variables in model 4 and BMI at age 20 years.
Model 6: adjusted for variables in model 5 and relative leg length.(0, 1-2, 3-4, 5+) did not materially alter the results
(RR = 1.19; 95% CI: 1.01, 1.41). As these factors are likely
to be on the exposure-outcome causal pathway (i.e., medi-
ators), they were not retained in the final model (model 4).
Adjustment for BMI at baseline–a major mediator on the
causal pathway–did attenuate the menarche age–diabetes
association (data not shown).
We did not observe evidence that associations differed
by age at interview (median split; <55 vs. ≥55 year),
race/skin color (black vs. white), maternal education
(<high school vs. ≥high school), birth weight (< 2500
vs. ≥ 2500 g), or BMI at 20 years (25 kg/m2 vs. ≥25 kg/m2).
Conclusions from our analyses including participants withdiabetes by menarcheal age in women aged 35-74 years
13–14 years 15–16 years 17-18 years
513/3181 158/912 37/204
1.0 (Ref.) 1.00 (0.86-1.18) 1.04 (0.77-1.40)
1.0 (Ref.) 0.96 (0.82-1.13) 0.99 (0.73-1.33)
1.0 (Ref.) 0.97 (0.83-1.13) 0.98 (0.73-1.32)
1.0 (Ref.) 0.95 (0.81-1.11) 0.98 (0.73-1.31)
1.0 (Ref.) 0.97 (0.82-1.13) 1.05 (0.79-1.41)
1.0 (Ref.) 0.97 (0.83-1.14) 1.07 (0.80-1.44)
betes.
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terially different from those that excluded participants with
missing birth weight.
In additional analyses among women not taking
diabetes medications (n = 7,192– 7,396, depending on
outcome), earlier menarche [< 11 years vs. 13-14 years
(referent)] was associated with higher % A1C (p < 0.001),
modestly associated with higher insulin concentrations
(p = 0.07) and 2-hour post load glucose (p = 0.09; only
analyzed in 7,100 women without previously diagnosed
diabetes), but was not associated with fasting glucose
(p = 0.68) (Table 3). Earlier menarche [< 11 years vs.
13-14 years (referent)] was also associated with ele-
vated alanine aminotransferase (p < 0.001), triglycerides
(p < 0.001), high sensitivity CRP (p = 0.003), waist circum-
ference (p < 0.001), and BMI (p < 0.001) measured at
enrollment (Table 3). Later age at menarche [17-18 years
vs. 13-14 years (referent)] was associated with higher CRP
(p = 0.01) but not with other cardiometabolic disease risk
factors analyzed (all p > 0.05).
Discussion
In this large cohort of Brazilian adults who were born
and came of pubertal age before the economic and
epidemiologic transition in Brazil, menarche onset less
than 11 years was associated with higher risk of diabetes.
This association remained after adjustment for potential
confounders, including race, maternal education, paren-
tal diabetes, birth weight, relative leg length–a marker ofTable 3 Adjusted means and standard errors for indices of gl
according to age at menarche in women aged 35-74 years in
<11 years 11–12 years 13
*n (range) 536-579 2764-2864 28
Glycemic risk
% A1C 5.38 ± 0.03† 5.33 ± 0.01 5.
2-h post load glucose 130.2 ± 1.7 127.9 ± 0.7 12
Fasting glucose 104.1 ± 0.6 104.4 ± 0.3 10
Fasting insulin 8.3 ± 0.7 8.1 ± 0.3† 7.
Cardiometabolic risk
ALT 26.9 ± 0.7† 23.3 ± 0.3 23
Triglycerides 123.6 ± 2.8† 117.7 ± 1.3 11
HDL-cholesterol 61.9 ± 0.6 61.5 ± 0.3† 62
C-reactive protein 3.6 ± 0.2† 3.0 ± 0.1 3.
Body habitus
BMI 27.8 ± 0.2† 27.1 ± 0.1† 26
WC 88.9 ± 0.5† 87.3 ± 0.2† 86
Abbreviations: A1C glycated hemoglobin; ALT alanine aminotransferase; HDL high-de
Adjusted for study center, age at enrollment, race/color, maternal education, mater
*n varied for each continuous metabolic parameter included in the model, so the ra
diabetes underwent 2-hour post load glucose testing (n = 7,100).
†p < 0.05 when compared to menarcheal age category 13-14 years (referent).early-life nutritional status [30]–and BMI at age 20
years.
Our study provides estimates of average age at menar-
che in a sample of Brazilian women participating in a
large, free-living occupational cohort, born between
1934-1975 and raised during a period when the average
gross domestic product of Brazil increased by 81% [31].
The earlier age at menarche observed with younger
participants reflects the secular trend toward earlier age
at menarche in Brazil [18]. While this trend may have
been influenced by increases in childhood fatness, our
study, corroborating evidence from others [20,22], sug-
gests that the association between age at menarche and
adult diabetes is not accounted for by early-life BMI.
Our study adds an important piece of evidence to the
literature base on this topic, showing that early menarche
was associated with diabetes after full multivariable
adjustment-including BMI at age 20 years-in Brazilian
adults born and raised in an era when childhood stunting
was more common (26.7%) than overweight (8.6%) [32].
Our findings largely align with literature on this topic
from Asian cohorts that had low rates of childhood
overweight/obesity and lived through rapid epidemio-
logic and nutritional transition after coming of pubertal
age. Conway et al. found that in 69,385 middle-aged
adult Chinese women from the Shanghai Women’s Health
Study, a 1-year increment in menarcheal age was asso-
ciated with a 5% lower risk of diabetes; this association
was attenuated upon adjustment for BMI measured whenycemic risk, cardiometabolic risk, and body habitus
ELSA-Brasil not taking diabetes medications
–14 years 15–16 years 17–18 years F-test p
18-2930 804-831 178-185
30 ± 0.01 5.31 ± 0.02 5.31 ± 0.05 0.048
7.0 ± 0.7 128.8 ± 1.4 128.7 ± 2.9 0.43
3.8 ± 0.3 103.6 ± 0.5 104.9 ± 1.1 0.54
0 ± 0.3 7.1 ± 0.5 7.2 ± 1.2 0.057
.1 ± 0.3 22.2 ± 0.6 24.0 ± 1.2 <.001
5.6 ± 1.2 112.9 ± 2.3 114.7 ± 4.9 <.001
.5 ± 0.3 61.8 ± 0.5 61.6 ± 1.1 0.16
0 ± 0.1 3.0 ± 0.2 3.9 ± 0.3† 0.005
.4 ± 0.1 26.5 ± 0.2 26.7 ± 0.3 <.001
.2 ± 0.2 86.8 ± 0.4 87.2 ± 0.8 <.001
nsity lipoprotein; BMI body mass index; WC waist circumference.
nal diabetes, paternal diabetes, birth weight, and BMI at age 20 years.
nge of n is included in parentheses; only those without previously diagnosed
Mueller et al. Cardiovascular Diabetology 2014, 13:22 Page 6 of 8
http://www.cardiab.com/content/13/1/22participants were 40-70 years [24]. In the Singapore
Chinese Health Study, menarche at or before 12 years
of age (compared to 13-14 years) was associated with
an 18% increased risk of diabetes even after adjust-
ment for BMI self-reported when participants were
aged 45-74 years [25]. In a study of 3,304 post-menopausal
women from Fujian, China, age at menarche did not ap-
pear to be associated with diabetes, but the earliest ca-
tegory of menarche age in this analysis was 9-14 years
thus potentially masking an association between diabetes
and early menarche as defined by our study (<11 years) [26].
Studies from countries with longer-standing economic
prosperity have also reported an association between
earlier menarche and increased risk of diabetes [19-23].
Similar to findings from more recently transitioned pop-
ulations, evidence from Western societies suggests the
menarcheal age-diabetes association is independent of
confounding by BMI. Findings from our study indicate
the association between early age at menarche and
diabetes is not explained by BMI at 20 years of age (the
earliest measure of BMI in our cohort). These results are
consistent with those from a British birth cohort [22],
the EPIC-InterAct study [33], and the ARIC study [20],
which found that BMI measured pre-menarche, at age
20, and at age 25, respectively, did not explain the age at
menarche-diabetes association. Furthermore, of the
studies mentioned herein, ours was the first to find that
age at menarche was associated with diabetes inde-
pendent of relative leg length, indicating these markers
represent different aspects of early-life growth and
development.
The mechanisms underlying the association between
age at menarche and type 2 diabetes are likely myriad
and interrelated. One extensively studied pathway is the
triggering of puberty by adipocytes and related hormones.
Accretion of fat (and therefore increased leptin) has been
shown to promote hypothalamic gonadotropin releasing
hormone pulse generator activity [34,35], and, thereby,
attenuate gonadal feedback suppression of luteinizing
hormone secretion [36] and augment aromatase activity
in the ovarian granulosa cells [37]. However, our find-
ings, which were largely independent of BMI at 20 years
of age, provide evidence that some independent direct
effect, acting through additional biological pathways,
may be at play.
Earlier menarche was associated with higher levels of
insulin like growth factor (IGF)-I, androstenedione, dehy-
droepiandrosterone sulfate (DHEAS), leptin, and fasting
insulin, and with lower levels of IGF binding protein-I,
and sex hormone binding globulin (SHBG) at age 8 years
in a study of 329 girls [38]. IGF-I, androstenedione, and
DHEAS remained associated with earlier menarche after
adjustment for BMI and height, suggesting independent
functional roles of these hormones, which have beenassociated with low birth weight and early catch up weight
gain, in regulating puberty timing in girls [38].
Insulin-resistance induced hyperinsulinemia manifesting
early in life may be an important pathologic perturbation
contributing to the observed association between earlier
age at menarche and higher diabetes risk. Randomized
controlled trials in low-birth weight, precocious-puberty
girls have shown that administration of metformin, an
insulin-sensitizing medication commonly used to treat
type 2 diabetes, delayed age at menarche and improved
post-menarcheal (up to 15 years of age) insulin resistance,
inflammation, liver fat content, and other pernicious
metabolic parameters [39-42]. Further research from cell,
animal, and human experiments is needed to shed etio-
logic light on the interplay of adiposity, insulin resistance,
inflammation, the IGF axis, SHBG, and sex hormones,
among other biologic intermediaries in the association of
earlier menarche with diabetes.
A novel finding from our study was the association
between earlier menarche and elevated alanine amino-
transferase, triglycerides, and high sensitivity C-reactive
protein. This is the first evidence, to our knowledge,
linking menarcheal age with markers of liver dysfunction
and inflammation. One hypothesis is that these associa-
tions are driven by an underlying association between age
at menarche and non-alcoholic steatohepatitis–otherwise
known as the hepatic manifestation of the metabolic syn-
drome [43]. While studies finding that early maturing
women had higher risk of the metabolic syndrome and its
components provide indirect support for this hypoth-
esis [44-47], observational and experimental research
is needed to directly examine the potential link of pubertal
timing with liver steatosis and inflammation.
This current study took advantage of a rich database in
a unique population to study the role of age at menarche
in relation to adult diabetes and other cardiometabolic
disease risk factors. The fact the association was little
changed after adjustment for participant age at enroll-
ment, and factors related to menarcheal age and type 2
diabetes that may vary across birth cohorts, such as preva-
lence of paternal diabetes, education, birth weight, and
early adulthood BMI, makes it very unlikely that the
association between age at menarche and diabetes is due
merely to a correlation between secular trends of increa-
sing diabetes prevalence and decreasing age at menarche
in Brazil.
An important limitation to consider when interpreting
the results of this analysis was the self-recall of menar-
cheal age many years after the event; thus, misclassifica-
tion was inevitable. However, adulthood retrospective
reports of age at menarche are highly correlated (r = 0.79)
with original adolescent reports [28]. One might also
consider the cross-sectional nature of the data collection
a limitation. Yet, in our cohort, all diabetes diagnoses
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dent in relation to age at menarche. We cannot rule out
the potential for residual confounding by factors related to
both age at menarche and type 2 diabetes. For example,
ELSA-Brasil does not have childhood anthropometry (e.g.,
BMI) or physiologic measures. Childhood fatness and
related hormones may cause early puberty and diabetes.
To address this concern, we adjusted for BMI (based on
self-reported weight) at age 20 years which, based on evi-
dence [48] that BMI tracks well through life, may proxy
pre-pubertal BMI.
Understanding how factors along the life course
impact type 2 diabetes and cardiometabolic disease risk,
and how such factors can be cost-effectively and sustain-
ably modified, are among the transcendent public health
challenges of our time. These challenges are especially
critical for population health in low- and middle-income
countries, including those in South America, in which
changing demographics, in addition to behavioral and
environmental risks, are producing rapid increases in
diabetes, and where the alternative to risk factor preven-
tion–the widespread use of costly drug- and device-related
interventions–is neither practical nor cost-effective. As
such, beyond its potential for extending quality years of
life, investigation into the primordial prevention of type 2
diabetes and other cardiometabolic diseases is critically
important to the future economic viability of health care
globally.Conclusion
These findings support the hypothesis that earlier age at
menarche (in our study, less than 11 years) is associated
with higher risk of adult diabetes and cardiometabolic
disease risk factors, permitting the possibility that pubertal
timing plays an independent role in the developmental
origins of adult chronic disease. This research provides a
platform for exploring the myriad behavioral and environ-
mental factors that may alter pubertal timing landmarks,
such as menarche, and thereby increase cardiometabolic
disease risk. Continued research in this primordial-
prevention realm may hold promise for curbing the rise
in metabolic and cardiovascular diseases in low- and
middle-income countries like Brazil.Consent
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